(IPCI) 5 Drugs under review by FDA (Mcap 47 M )= MULTIBAGGER

[Biotechmaster]

This Unknown low float Stock awaiting 5 FDA approvals .Cash burn is very low means they will be profitable very soon after first product launch .

Par Pharma (PRX) is the second largest Shareholder and Marketing Partner for Focalin which will be approved soon .

Market Cap of 47 Mil is really a BIG JOKE .They have enough cash to run their Company into profitable business .


I think $15++ is very realistic for 2011 .GL


Intellipharmaceutics (IPCI)

Market Cap: 47 M
Cash: 13 M
Price: 2.97 $

Shares Out: 15.9 M.. ( 8 Million shares held by CEO)


Monster Pipeline



New Presentation ..CHECK IT OUT !!!



Intellipharmaceutics Submits 4th ANDA in 12 Months



Great Article ..A must READ



Another great Article



Intellipharmaceutics now has five ANDAs awaiting FDA approval with reported sales for branded and generic versions of these products being approximately $8 billion in 2010. The Company develops both ANDA product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway.


Intellipharmaceutics' development milestones for 2011 include the following:

Obtain FDA approval of our generic version of Focalin XR(R)

Have two additional ANDA applications accepted for filing by FDA

Establish at least one additional development/marketing alliance

Complete manufacturing of clinical batches of Rexista(TM) oxycodone

Initiate Phase I studies using clinical batches of Rexista(TM)oxycodone

Schedule a pre-IND meeting with FDA to discuss Rexista(TM) oxycodone clinical development plan

[Biotechmaster]

The investors still not realise the real Value of this MEGA News from December . Protonix alone could make IPCI profitable and there are still many Drugs awaiting FDA approval . IPCI is very very Cheap but not for long thats for sure .GL
---

On December 22, 2010, IPCI announced that it had not been notified by Wyeth Pharmaceuticals of any patent infringement proceedings relating to IPCI

[Biotechmaster]

NEW ARTICLE ....A MUST READ !!! Now you Know why this is a pure Goldmine .



CEO says multiple deals, FDA approvals and more filings are in the works

Thursday, 21 April 2011 01:02


As we first told our premium subscribers on Tuesday, the management team at Intellipharmaceutics (Nasdaq:IPCI )(TSX:I) is clearly excited about the progress they've been making. The pharmaceutical company specializies in the reformulation and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs and they are finally on the verge of going commercial in a big way. With multiple pending FDA approvals, we first profiled IPCI in detail in late January. The company caught our attention for several reasons. Among them is the fact that the reported sales for branded and generic versions of their pending approval products stands at close to $9 billion.

IPCI develops both ANDA (Abbreviated New Drug Application) product candidates and new drugs through the New Drug Application (NDA) 505(b)(2) regulatory pathway. Their CEO, Dr. Isa Odidi, is easily considered one of the sector's top drug delivery innovators. When Odidi was at Biovail- which merged with Valeant Pharmaceuticals International (NYSE: VRX)(TSX:VRX) in 2010, he was performing drug alchemy with formulations that mimicked several hard-to-manufacture generic versions of expensive drugs- among them, Pfizer